BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 1952872)

  • 1. In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin.
    Rastogi N; Goh KS
    Antimicrob Agents Chemother; 1991 Sep; 35(9):1933-6. PubMed ID: 1952872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
    Tomioka H; Sato K; Kajitani H; Akaki T; Shishido S
    Antimicrob Agents Chemother; 2000 Feb; 44(2):283-6. PubMed ID: 10639351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis.
    Piersimoni C; Morbiducci V; Bornigia S; De Sio G; Scalise G
    Am Rev Respir Dis; 1992 Dec; 146(6):1445-7. PubMed ID: 1333738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.
    Kocagöz T; Hackbarth CJ; Unsal I; Rosenberg EY; Nikaido H; Chambers HF
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1768-74. PubMed ID: 8843279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin.
    Vacher S; Pellegrin JL; Leblanc F; Fourche J; Maugein J
    J Antimicrob Chemother; 1999 Nov; 44(5):647-52. PubMed ID: 10552981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin.
    Tomioka H; Saito H; Sato K
    Antimicrob Agents Chemother; 1993 Jun; 37(6):1259-63. PubMed ID: 8392307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis.
    Ji B; Truffot-Pernot C; Grosset J
    Tubercle; 1991 Sep; 72(3):181-6. PubMed ID: 1663283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various mycobacteria].
    Kawahara S; Tada A; Nagare H
    Kekkaku; 2001 Apr; 76(4):357-62. PubMed ID: 11398326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Determination of antimycobacterial activities of fluoroquinolones against clinical isolates of Mycobacterium tuberculosis: comparative determination with egg-based Ogawa and agar-based Middlebrook 7H10 media].
    Yamane N; Chilima BZ; Tosaka M; Okazawa Y; Tanno K
    Kekkaku; 1996 Aug; 71(8):453-8. PubMed ID: 8831190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin.
    Chaudhry AZ; Knapp CC; Sierra-Madero J; Washington JA
    Antimicrob Agents Chemother; 1990 Sep; 34(9):1843-5. PubMed ID: 2285304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.
    Rotstein C; Amsterdam D; Beam TR; Mandell LA; Gorzynski EA
    Diagn Microbiol Infect Dis; 1993 Jul; 17(1):85-91. PubMed ID: 8395375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MICs and MBCs of Win 57273 against Mycobacterium avium and M. tuberculosis.
    Heifets LB; Lindholm-Levy PJ
    Antimicrob Agents Chemother; 1990 May; 34(5):770-4. PubMed ID: 2113793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of fluoroquinolones against Mycobacterium tuberculosis.
    Sulochana S; Rahman F; Paramasivan CN
    J Chemother; 2005 Apr; 17(2):169-73. PubMed ID: 15920901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS; Ahlén S
    Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone.
    Kim JH; Choi KH; Kim JW; Lee JH; Choi EC; Kim BK
    J Antimicrob Chemother; 1998 Feb; 41(2):223-9. PubMed ID: 9533464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin.
    Drugeon HB; Juvin ME; Bryskier A
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():55-9. PubMed ID: 10404339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae.
    George J; Morrissey I
    J Antimicrob Chemother; 1997 Jun; 39(6):719-23. PubMed ID: 9222040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds.
    Jones RN; Barrett MS; Erwin ME; Briggs BM; Johnson DM
    Diagn Microbiol Infect Dis; 1991; 14(4):319-30. PubMed ID: 1909615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.
    Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1992 Apr; 36(4):856-9. PubMed ID: 1323956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activities of new quinolones against coryneform bacteria.
    Martínez-Martínez L; Suárez AI; Ortega MC; Perea EJ
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1439-41. PubMed ID: 8092851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.